<DOC>
	<DOC>NCT02156349</DOC>
	<brief_summary>This study is a German, prospective, multicenter, controlled, cluster-randomized, interventional comparative study evaluating the efficacy and benefits of integrated PDM care by measuring HbA1c levels in patients with Type 2 Diabetes. Patients will be randomized into two groups to use Accu-Chek Smartpix software and Accu-Chek Smartpix device.</brief_summary>
	<brief_title>A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>existence of a signed Informed Consent form (before any study procedure) diagnosed Type 2 diabetes mellitus age ≥18 years insulin therapy for ≥6 months: BOT, SIT, CT or ICT HbA1c ≥7.5% (≥ 58,47 mmol/mol respectively), blood withdrawal for measurement in the last 90 days before study visit 1 (patient's inclusion) longerterm care (at least for the duration of the 12month study participation) by the trial site insured by the statutory health insurance (GKV) as a compulsory member or voluntarily insured member or as a family coinsured member willing and able to participate in the study and to follow the study procedures, among other things sufficient command of the German language, spoken and written Treatment of diabetes with insulin pump (CSII) Methodic and continuous with the use of particular software for processing of SMBG data by the patient and at visits in the practice by the physician/diabetes educator in the past 12 months before study participation.presence of terminal renal failure (eGFR &lt; 15ml/min) / dialysis and/or a loss of sight (visual acuity ≤ 0,05 of the better eye) Existing tumor illness (primary tumor/local recurrence/ metastases except Basal Cell Carcinoma) in the past 5 years before study participation newly diagnosed or treated acutely (hormone, chemo or radiation therapy). Within a tumor free time of &lt; 5 years Medical Affairs will decide about individual cases permanent use of steroids in adrenal suppressant doses, of other immunomodulatory drugs or chemotherapy known alcohol and drug abuse and medication abuse known metabolic disorders and/or disorders or therapies that could lead to or have led to wrong measured results (e.g. with the blood glucose measurement) existing pregnancy, breastfeeding or plan to become pregnant during study participation physical illness and/or psychological disorder with the result that the patient cannot implement the medical treatment recommendations independently dependency relationship to the sponsor or to the investigator, e.g. as a professional colleague or family member</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes</keyword>
</DOC>